Skip to content

Study · Randomized controlled trial · n = 41 · 2001

5 results

Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.

Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G, Crosignani PG

Human reproduction (Oxford, England)1 Nov 2001Cited by 50 (Europe PMC)

PMID11679500 (opens in a new tab)DOI10.1093/humrep/16.11.2258 (opens in a new tab)PepBankPUB-11679500
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In infertile patients, luteal progesterone increases were similar with cetrorelix plus recombinant FSH and recombinant FSH alone.

    In plain wordsIn infertile patients, luteal progesterone increases were similar with cetrorelix plus recombinant FSH and recombinant FSH alone.

    Peptide
    Cetrorelix
    Outcome
    No significant changeLuteal progesterone increase
    Study

    n = 41

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · From follicle diameter >=14 mm until HCG administrationAs given in this study (human).

    Source sentences

    Summary
    The two treatment groups showed a similar increase in progesterone concentration during the luteal phase.
    4 context sentences
    Summary · context
    Forty-one infertile couples were recruited in this randomized clinical study.
    Summary · context
    The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of > or =14 mm was seen at ultrasound scan.
    Summary · context
    Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration.
    Summary · context
    The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In infertile patients, mid-luteal oestradiol was lower with cetrorelix plus recombinant FSH than with recombinant FSH alone (P < 0.05).

    In plain wordsIn infertile patients, mid-luteal oestradiol was lower with cetrorelix plus recombinant FSH than with recombinant FSH alone.

    Peptide
    Cetrorelix
    Outcome
    DecreaseMid-luteal oestradiol
    Study

    n = 41

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · From follicle diameter >=14 mm until HCG administrationAs given in this study (human).

    Measurements

    P value, oestradiol group B vs group A
    < 0.05 P
    mid-luteal phase, day 6 after HCG

    Source sentences

    Summary
    In the mid-luteal phase (day 6 after HCG), oestradiol concentrations in group B were significantly higher compared with group A (P < 0.05) but the oestradiol:progesterone ratio was similar in the two groups.
    4 context sentences
    Summary · context
    Forty-one infertile couples were recruited in this randomized clinical study.
    Summary · context
    The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of > or =14 mm was seen at ultrasound scan.
    Summary · context
    Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration.
    Summary · context
    The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In infertile patients, mid-luteal oestradiol:progesterone ratios were similar with cetrorelix plus recombinant FSH and recombinant FSH alone.

    In plain wordsIn infertile patients, mid-luteal oestradiol:progesterone ratios were similar with cetrorelix plus recombinant FSH and recombinant FSH alone.

    Peptide
    Cetrorelix
    Outcome
    No significant changeMid-luteal oestradiol:progesterone ratio
    Study

    n = 41

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · From follicle diameter >=14 mm until HCG administrationAs given in this study (human).

    Source sentences

    Summary
    In the mid-luteal phase (day 6 after HCG), oestradiol concentrations in group B were significantly higher compared with group A (P < 0.05) but the oestradiol:progesterone ratio was similar in the two groups.
    4 context sentences
    Summary · context
    Forty-one infertile couples were recruited in this randomized clinical study.
    Summary · context
    The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of > or =14 mm was seen at ultrasound scan.
    Summary · context
    Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration.
    Summary · context
    The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In infertile patients, only cetrorelix plus recombinant FSH completely suppressed follicular serum LH, compared with recombinant FSH alone.

    In plain wordsIn infertile patients, only cetrorelix plus recombinant FSH completely suppressed follicular serum LH, compared with recombinant FSH alone.

    Peptide
    Cetrorelix
    Outcome
    DecreaseFollicular serum LH suppression
    Study

    n = 41

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · From follicle diameter >=14 mm until HCG administrationAs given in this study (human).

    Source sentences

    Summary
    Serum LH was completely suppressed during the follicular phase only in group A, concomitantly with GnRH antagonist administration.
    4 context sentences
    Summary · context
    Forty-one infertile couples were recruited in this randomized clinical study.
    Summary · context
    The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of > or =14 mm was seen at ultrasound scan.
    Summary · context
    Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration.
    Summary · context
    The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In infertile patients, ongoing pregnancies were equally distributed between cetrorelix plus recombinant FSH and recombinant FSH alone.

    In plain wordsIn infertile patients, ongoing pregnancies were equally distributed between cetrorelix plus recombinant FSH and recombinant FSH alone.

    Peptide
    Cetrorelix
    Outcome
    No significant changeOngoing pregnancies
    Study

    n = 41

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · From follicle diameter >=14 mm until HCG administrationAs given in this study (human).

    Measurements

    Pregnancies, all ongoing
    6 pregnancies
    both groups combined
    Pregnancy rate per patient
    14.3%
    both groups combined
    Pregnancy rate per cycle
    12.2%
    both groups combined

    Source sentences

    Summary
    A total of six pregnancies, all ongoing, were achieved (14.3% per patient and 12.2% per cycle), equally distributed in group A and in group B.
    4 context sentences
    Summary · context
    Forty-one infertile couples were recruited in this randomized clinical study.
    Summary · context
    The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of > or =14 mm was seen at ultrasound scan.
    Summary · context
    Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration.
    Summary · context
    The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.